The integration of synthetic antigen receptors into immune cells has emerged as a potent approach for treating various diseases, particularly through the use of T cells engineered to express chimeric antigen receptors (CAR) for targeted cancer therapy. However, in addition to T lymphocytes, B lymphocytes also hold great potential as immune cells that can be genetically modified for therapeutic purposes, such as the production of recombinant antibodies or protein replacement therapy. To this end, CAR-B cells are a promising avenue for achieving localized delivery of monoclonal antibodies to tumor sites by targeting specific tumor-associated antigens (TAA).

Creative Biolabs has developed an innovative design for a new class of synthetic antigen receptors, known as chimeric B cell receptors (CBCR). The Anti-HEL (HyHEL10) h(scFv-CD28TM-CD79_) CBCR(CAR-B) vector is composed of an anti-HEL antibody-based binding domain, which is fused with the CD79_ signaling domain, a component of the B cell receptor (BCR) complex that is responsible for activation. This vector can be introduced into primary murine B cells, resulting in high levels of surface expression and antigen recognition, independent of the endogenous BCR.